4 ms·
A biotech startup has one similar thing to a hitech startup - and that's that the predominant exit strategy is to 'get bought out by a big player'. In my opini
by dnautics 12y ago
A biotech startup has one similar thing to a hitech startup - and that's that the predominant exit strategy is to 'get bought out by a big player'. In my opinion, the market isn't awash in pharma startups, because of three factors. 1) high capital costs. 2) most pharma startups are started by professors; the selection process for professors is in many ways orthogonal to 'success in developing pharmaceuticals'. 3) Labor talent. Because of the now about decades-long (over/mal)investment in STEM, there has been a glut of PhDs with questionable qualifications, that flood the labor market.
I don't generally argue the 'greed drives things' argument. No, pharma companies don't want big margins necessarily out of greed, but the momentum, machine, and in certain cases legal infrastructure (requirements of companies to provide returns to investors, etc) align in such a way that dislodging big pharma from its position of legal entitlement is politically intractable, because they will fight for it, whether dominantly greed-motivated or not.
- dnautics 12y agoSpeaking to #3, and this is highly anecdotal - I spent 6 years in grad school that was highly ranked (I loathe the ranking system, but that may be irrelevant). And had about 70 students a year. Over my 6 years, I saw maybe 20 good thesis defenses (my own was not very good). One particular lab was a serial offender; exactly zero of the defenses I saw I thought were worthy of a PhD (although I recall two projects there that I thought were good that were not concluded when I finshed). One of these defenses had a presentation where the introductory slide bulleted six topics of study that the student completed; he presented only four of the six and all of them failed, two of them, as admitted by the student himself, for trivial reasons that could have been solved by merely sauntering over to his committee member's and chatting for five minutes. This person still has a PhD from a top institution. His boss has several startup companies, all completely rediculous (one of which seeks to eliminate cocaine addiction through something which will probably only make the cocaine addiction worse - it then pivoted to "an emergency drug to administer to accidental cocaine overdoses"). My experiences witnessing thesis defenses as a postdoc at a "mid-tier" research university were not much better.